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ABSTRACT: 4,4-Disubstituted 4H-isoxazol-5-ones bearing a 1,4-naphthoquinone moiety undergo transformation into 
different type of benzoindolyl products depending on the different reaction conditions. A decarboxylative ring-open-
ing/ring closure promoted by catalytic [Ru(p-cymene)2Cl2]2 yields benzo[f]indole-4,9-diones. Alternatively, hydrogena-
tion reactions provide the conversion of 4-(1,4-naphthoquinone)-substituted isoxazol-5-ones to benzo[g]indole com-
pounds, with the level of reduction depending on the substituents present on the ring. Starting materials have been 
easily prepared by functionalization of isoxazolinones with naphthoquinone in mild conditions. 
4H-Isoxazol-5-ones  have  been  identified  in  organic 
synthesis as versatile building blocks thanks to their ease 
of functionalization and of ring opening.1 In particular, 
the isoxazolinone ring can be converted into either acylic 
compounds, such as azadienes2 and alkynes,3 or hetero-
cyclic structures such as pyridines,4  azirines,5  imidazo-
les,6 1,3-oxazines,7 pyrazin-2-ones8 and piperidines.9
Following  our  continuous  interest  in  aza-heterocy-
cles10 in general, and in isoxazolin-5-ones in particular,11 
and considering the role of transition metal complexes 
such those based on ruthenium,4a,4c,5a  iridium,5b  iron,4d 
and palladium4b,5c,9 in the decarboxylative conversion of 
isoxazol-5-ones (Scheme 1, eqs. 1-3), we envisioned the 
4-(1,4-naphthoquinone)-substituted  4H-isoxazol-5-ones 
as possible precursors of new benzo-fused indoles. We 
describe  herein  their  divergent  conversion  into 
benzo[f]indole-4,9-diones  and  benzo[g]indole  deriva-
tives in the presence of Ru(II)-catalysts or by Pd/C-cat-
alyzed hydrogenation, respectively (Scheme 1, eqs. 4,5).
Scheme 1.  Transition metal-catalyzed decarboxylative 
conversion of isoxazol-5-ones to different heterocycles 
!
Benzo-fused indole moieties are key structural blocks 
in  many  biologically  natural  or  synthetic  compounds. 
Among them, benzo[f]indole-4,9-diones play a relevant 
role due to their  pronounced biological  activity as an-
tibacterial,  antiviral,  antifungal,  anticancer, and anti-in-
flammatory.12  Benzo[g]indole  derivatives  have  shown 
anticancer,  anti-inflammatory  and  antipsychotic  activi-
ties.13 Moreover, the latter compounds have found inter-
est in material sciences.14 Several methodologies for their 
preparation  have  been  reported.15,16  However,  in  this 
context,  the  development  of  new  efficient  procedures 
based on the use of readily available starting materials 
continues to be a challenging target. Thus, the innovative 
reactivity  herein  reported  provides  step-economic 


































































eq. 5 eq. 4
This work
benzo[g]indole  compounds  through  decarboxylative 
ring-opening/ring-closure  of  4-naphthoquinonyl  isoxa-
zol-5-ones. 
Our investigation began with the preparation of the 
reaction precursors  2a-j,  obtained by treatment  of  1,4-
naphthoquinone under basic conditions with the corre-
sponding  isoxazolones  1a-j,  in  turn  readily  accessible 
from hydroxylamine and β-ketoesters or malonates, ac-
cording to a published protocol (Scheme 2).17
Scheme 2. Preparation of 4-(1,4-naphthoquinone)-sub-
stituted isoxazolin-5-ones 2
!
a Reaction conditions: 1a-j (1.0 mmol), 1,4-naphthoquinone (1.0 
mmol), Et3N (0.10 mmol), CH2Cl2 (5 mL). 
4-Methyl-4-naphthalene-1,4-dione-2-yl-3-phenyl-sub-
stituted isoxazolone 2a  was  chosen as  the  model  sub-
strate  to  carry  out  preliminary  experiments.  The  reac-
tions tested in search for optimized conditions are sum-
marized in  Table  1.  Initially,  the  substrate  was treated 
with  the  commercial  [Ru(p-cymene)Cl2]2  in  catalytic 
amount  using  different  solvents.  While  heating  in 
toluene at 100 °C left the substrate unchanged (Table 1, 
entry 1), addition of DMF (20 vol%) led to small amount 
of the benzo[f]indole-4,9-dione 3a, arising from a decar-
boxylative  ring-opening/ring  closure  process,  beside 
unaltered starting material (entries 2 and 3, Table 1). Us-
ing DMSO as co-solvent strongly increased the forma-
tion of compound 3a, while the loading of catalyst was 
found to be irrelevant for the reaction (entries 4 and 5, 
Table 1). Due to the low solubility of the substrates, the 
yield was improved working in DMSO as the sole sol-
vent at 100 °C (entry 6, Table 1). The addition of phen-
athroline as a ligand in reactions carried out in toluene/
DMSO or DMSO did not provide higher product yields 
(entries 7 and 8, Table 1). When working at room tem-
perature, no conversion of the substrate was observed, 
while lowering the reaction temperature from 100 to 80 
°C resulted in  a  drastic  decrease  of  the  yield  (82% vs 
14%)  (entries  9  and  10,  Table  1).  A different  type  of 
ruthenium catalyst such as Ru3(CO)12 afforded the prod-
uct  in  very  low  yield   (entry  11,  Table  1).  Then,  we 
turned our attention to other transition metal complexes. 
The  use  of  [IrCl(cod)]2  afforded  3a  only  in  moderate 
yields  from  a  complex  mixture  of  degradation  com-
pounds (entries 12-14, Table 1). The palladium complex-
es Pd2(dba)3 and Pd(PPh3)4, applied under different con-
ditions, left the substrate unchanged (entries 15-18, Table 
1).  Pd-catalysis  under  hydrogen  atmosphere  was  also 
tested, in the hope of obtaining reaction through the in-
termediacy  of  a  vinylnitrene-Pd  species.4b  Although 
Pd(PPh3)4 left  the substrate unchanged (entry 19, Table 
1), the use of catalytic amounts of Pd/C in the presence 
of H2 atmosphere provided the benzo[g]indole-5-one 4a 
as  the  major  product,  isolated in  65% yield  (entry  20, 
Table 1).

























a: R' = Ph; R'' = Me f: R' = CO2Et; R'' = Me
g: R' = Me; R'' = Bn
h: R' = Me; R'' = CH2CO2Me
i: R' = Me; R'' = CH2CH2Ph
j: R', R'' = -(CH2)4-
d: R' = Ph; R'' = CH2(CH2)4-Me
e: R' = Ph; R'' = CH2CO2Et
c: R' = Ph; R'' = Bn































1 [ R u ( p -
cymene)Cl2]2
toluene 100c S.M.




















6 [ R u ( p -
cymene)Cl2]2
DMSO 100e 3a (82)





8 [ R u ( p -
cymene)Cl2]2f
DMSO 100e 3a (76)
9 [ R u ( p -
cymene)Cl2]2
DMSO r.t.e S.M.
10 [ R u ( p -
cymene)Cl2]2
DMSO 80e 3a (14)







14 [IrCl(cod)]2 DMSO 100e 3a (38)
15 Pd2(dba)3 dioxane 80c S.M.
16 Pd2(dba)3g dioxane 80e S.M.
a Reaction conditions: 2a (1.0 mmol), catalyst (0.05 mmol), solvent (3 
mL), reported temperature, 24 or 48 h. b 5 mol%, unless otherwise 
indicated. c Reaction time: 24 h. d 10 mol%. e Reaction time: 48 h. f 
Phenanthroline (20 mol%) was added. g PPh3 (20 mol%) was added. 
h H2 atmosphere. i overnight. j in 10:1 ratio. 
To evaluate the scope of the decarboxylative cycliza-
tion to yield benzo[f]indole-4,9-dione derivatives, condi-
tions of Table 1, entry 6, were applied to 4H-isoxazol-5-
ones 2b-j bearing alkyl and phenyl groups. With excep-
tion of the 2-phenyl-3-benzyl-substituted benzo[f]indole 
3c, the decarboxylative ring-opening/ring closure prod-
ucts  were  isolated  in  a  satisfactory  range  of  60-75% 
yields (Scheme 3). Interestingly, the decarboxylative cy-
clization is not precluded by the presence of a carboxy-
late group at 3-position (substrate 2f) or a chain at 4-po-
sition of the starting isoxazolone ring (substrates 2e and 
2h).
Scheme 3. Scope of the decarboxylative cyclization of 
the 4H-isoxazol-5-ones 2b-ja
a  Reaction  conditions:  2  (1.0  mmol),  [Ru(p-cymene)Cl2]2  (0.05 
mmol), DMSO (3 mL), 100 °C. b Reaction time: 48 h. c Reaction time: 
24 h.  
 A plausible  mechanism  for  this  transformation  is 
depicted in Scheme 4.  Initial  oxidative addition of  the 
ruthenium catalyst to the N-O bond of 2  generates the 
iminocarboxylate-Ru complex A, which converts to the 
vinyl-nitrene-Ru intermediate B by loss of carbon diox-
ide.5a The ring-closure involves an electrocyclic reaction 
leading to the azaruthenacycle C, followed by reductive 
elimination with formation of the product 3 and regen-
eration of the Ru-catalyst. 
Scheme  4.  The  proposed  mechanism  of  Ru(II)-cat-
alyzed reaction
  
After  having  confirmed  the  ability  of  [Ru(p-
cymene)Cl2]2  to  convert  4H-isoxazol-5-ones  into 
benzo[f]indole-4,9-diones,  we delved into  the  result  of 
Table 1, entry 20, to verify if a simple protocol change on 
the same type of  substrates allows a general  access to 
benzo[g]indole-5-one derivatives. 
The applicability of the hydrogenolytic conditions to 
achieve benzo[g]indole-5-one derivatives was evaluated 
considering the compounds 2b-j and the results are col-
lected in Scheme 5. In the event, all the substrates tested 
using  the  system  [Pd/C,  H2  (1  atm)]  provided  com-
pounds with benzo[g]indole structures resulting from an 
alkene  hydrogenation.  In  particular,  while  a  phenyl 
group  at  position  2  generates  the  2H-
benzo[g]indol-5(3H)-ones  derivatives,  an  alkyl  or  an 
alkoxycarbonyl  group  was  found  to  favor  1H-
benzo[g]indol-5-ols or 3H-benzo[g]indol-5-ols. Thus, the 
2-phenyl-substituted 4H-isoxazol-5-ones 2b-e  furnished 
the 2,3-dihydro-benzo[g]indol-5-ones 5b-e  as the major 
products, isolated in 52-68% (entries 1-4, Scheme 5). An 
ethoxycarbonyl group at position 2 (2f) afforded the 5-
hydroxy-1H-benzo[g]indole 6f  (entry 5, Scheme 5). The 
same kind of structure was obtained working with the 2-
methyl-substituted substrate 2g,  which furnished 6g  in 
69%  yield  (entry  6,  Scheme  5).  Conversely,  2-methyl-
17 Pd(PPh3)4 DMSO 100c S.M.
18 Pd(PPh3)4g DMSO 100c S.M.
19 Pd(PPh3)4h AcOEt r.t.i S.M.
20 Pd/Ch A c O E t /
DMFj








































isoxazolones 2h-j afforded 3H-benzo[g]indole structures. 
In  the  case  of  substrates  2h  and 2i,  these  compounds 
were obtained only as the minor products (entries 7 and 
8, Scheme 5). In fact, in the former case, the compound 
7h was recovered in 18% yield together with the imino-
lactone 8, isolated in 55% yield, while in the second case 
the derivative 7i was formed competitively with the 4,8-
dihydroxy-benzo[f]indole 9. Finally, isoxazolone 2j gave 
the tetracyclic product 7j as the major products, isolated 
in its pure state in 63% yield (entry 9, Scheme 5).
Scheme 5. The scope of the catalytic hydrogenation of 
the 4H-isoxazol-5-ones 2b-ja
 
a  Reaction  conditions:  substrate  2b-j  (1.0  mmol),  Pd/C  (10% 
weight), AcOEt (30 mL), r.t., H2 atmosphere, overnight.
A mechanism for this second transformation is depic-
ted in Scheme 6. The initial hydrogenolytic cleavage of 
the labile N-O bond of the isoxazolone ring18 affords a β-
imino-carboxylic  acid  intermediate.  Subsequent  de-
carboxylation19 generates an enamine that, through cyc-
locondensation with the vicinal carbonyl group, gener-
ates the corresponding naphthoquinone 4. The following 
alkene hydrogenation affords compounds 5  or (6  or 7) 
depending on the nature of the substituent at position 3 
of the isoxazolone ring (Scheme 6).
Scheme 6. Proposed mechanism for the Pd/C catalyzed 
hydrogenation reaction of 4H-isoxazol-5-ones 2
!
In summary, we have disclosed new approaches for 
the synthesis of two types of benzannulated indoles by 
the conversion of stable and readily accessible 4H-isoxa-
zol-5-ones. The reactions occur either by ruthenium cata-
lysis  or  Pd/C  catalyzed  hydrogenation,  affording 
benzo[f]indole-4,9-dione and benzo[g]indole derivatives, 
respectively. Both processes involve an initial decarboxy-
lative ring opening of the isoxazolone moiety. The ring 
closure is expected to proceed through C-H functionali-
zation of the naphthoquinone under Ru catalysis. These 
strategies represent a valuable alternative to the methods 
already reported in the literature for the preparation of 
benzo-indoles and provide wide the possibilities to use 
the 4H-isoxazol-5-ones as building blocks to access hete-
rocyclic products. Further work is aimed to investigate 
transition metal-based conditions to convert isoxazolone 
derivatives to pyrroles.
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